NFL-TBS.40-63 Peptide Gold Complex Nanovector: A Novel Therapeutic Approach to Increase Anticancer Activity by Breakdown of Microtubules in Pancreatic Adenocarcinoma (PDAC).
Journal
ACS pharmacology & translational science
ISSN: 2575-9108
Titre abrégé: ACS Pharmacol Transl Sci
Pays: United States
ID NLM: 101721411
Informations de publication
Date de publication:
09 Dec 2022
09 Dec 2022
Historique:
received:
11
08
2022
entrez:
16
12
2022
pubmed:
17
12
2022
medline:
17
12
2022
Statut:
epublish
Résumé
The role of the NFL-TBS.40-63 peptide is to destroy the microtubule network of target glioma cancer cells. Recently, we have conceived a gold-complex biotinylated NFL-TBS.40-63 (BIOT-NFL) to form a hybrid gold nanovector (BIOT-NFL-PEG-AuNPs). This methodology showed, for the first time, the ability of the BIOT-NFL-PEG-AuNPs to target the destruction of pancreatic cancer cells (PDAC) under experimental conditions, as well as detoxification and preclinical therapeutic efficacy regulated by the steric and chemical configuration of the peptide. For this aim, a mouse transplantation tumor model induced by MIA-PACA-2 cells was applied to estimate the therapeutic efficacy of BIOT-NFL-PEG-AuNPs as a nanoformulation. Our relevant results display that BIOT-NFL-PEG-AuNPs slowed the tumor growth and decreased the tumor index without effects on the body weight of mice with an excellent antiangiogenic effect, mediated by the ability of BIOT-NFL-PEG-AuNPs to alter the metabolic profiles of these MIA-PACA-2 cells. The cytokine levels were detected to evaluate the behavior of serum inflammatory factors and the power of BIOT-NFL-PEG-AuNPs to boost the immune system.
Identifiants
pubmed: 36524008
doi: 10.1021/acsptsci.2c00159
pmc: PMC9745895
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1267-1278Informations de copyright
© 2022 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Am J Surg Pathol. 2001 Sep;25(9):1167-73
pubmed: 11688576
Immunity. 2019 Apr 16;50(4):1007-1023
pubmed: 30995492
Adv Pharm Bull. 2017 Sep;7(3):339-348
pubmed: 29071215
Comp Med. 2015 Apr;65(2):96-113
pubmed: 25926395
Sci Rep. 2021 Feb 5;11(1):3208
pubmed: 33547353
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
Chem Biol Interact. 2010 Jun 7;186(1):90-5
pubmed: 20338156
Signal Transduct Target Ther. 2018 Mar 16;3:7
pubmed: 29560283
Br J Clin Pharmacol. 2017 Feb;83(2):255-268
pubmed: 27620987
Am J Pathol. 2004 Jul;165(1):35-52
pubmed: 15215160
ACS Appl Mater Interfaces. 2016 Aug 10;8(31):19946-57
pubmed: 27424920
Oncol Res Treat. 2018;41(4):164
pubmed: 29587285
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
Nanoscale Adv. 2022 May 12;4(14):3010-3022
pubmed: 36133522
ACS Nano. 2016 Dec 27;10(12):10631-10635
pubmed: 28024339
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Med Oncol. 1996 Sep;13(3):133-40
pubmed: 9106171
Gastroenterology. 2013 Jun;144(6):1220-9
pubmed: 23622131
J Neurosci. 2009 Sep 2;29(35):11043-54
pubmed: 19726663
Biochim Biophys Acta. 2007 Jul;1768(7):1769-76
pubmed: 17499577
Cold Spring Harb Perspect Biol. 2018 Jun 1;10(6):
pubmed: 29858272
Nanoscale Adv. 2021 Aug 19;3(21):6144-6156
pubmed: 36133939
Clin Sci (Lond). 2020 Aug 28;134(16):2091-2115
pubmed: 32808663
Front Cardiovasc Med. 2019 Sep 20;6:141
pubmed: 31620451
Biomaterials. 2008 Apr;29(12):1912-9
pubmed: 18242692
Int J Biol Macromol. 2014 Mar;64:276-80
pubmed: 24315949
PLoS One. 2014 Jun 04;9(6):e98473
pubmed: 24896268
Int J Nanomedicine. 2016 Feb 26;11:791-822
pubmed: 27013874
Clin Immunol. 2009 Jan;130(1):27-33
pubmed: 18845487
Nanomedicine (Lond). 2011 Jun;6(4):715-28
pubmed: 21718180
Cytokine. 2015 Oct;75(2):261-71
pubmed: 26113402
Front Oncol. 2021 May 21;11:640863
pubmed: 34094924
Therap Adv Gastroenterol. 2013 Jul;6(4):321-37
pubmed: 23814611
J Exp Clin Cancer Res. 2021 Mar 17;40(1):102
pubmed: 33731188
Nanotheranostics. 2021 Apr 22;5(4):405-416
pubmed: 33912380
ACS Nano. 2020 May 26;14(5):5874-5886
pubmed: 32348119
J Mater Chem. 2009 Jan 1;19:4655-4672
pubmed: 20305738
Chem Soc Rev. 2018 May 21;47(10):3574-3620
pubmed: 29479622
Front Oncol. 2014 Jun 18;4:153
pubmed: 24995158
Cancer Immunol Res. 2019 Mar;7(3):498-509
pubmed: 30728152
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5815-24
pubmed: 26392551
World J Gastroenterol. 2015 Jun 14;21(22):6924-30
pubmed: 26078569
IUBMB Life. 2008 Mar;60(3):165-70
pubmed: 18380008
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Cancers (Basel). 2022 Jan 21;14(3):
pubmed: 35158814
Clin Cancer Res. 2018 Jan 15;24(2):460-473
pubmed: 29084920
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Transfus Med Rev. 2020 Oct;34(4):209-220
pubmed: 33051111
J Exp Med. 1994 Apr 1;179(4):1109-18
pubmed: 8145033
Genes Dis. 2015 Jun 1;2(2):133-143
pubmed: 26114155
Cancer Res. 2010 Dec 15;70(24):10192-201
pubmed: 21159641
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Curr Opin Genet Dev. 2008 Feb;18(1):11-8
pubmed: 18308558
Nanomedicine (Lond). 2008 Oct;3(5):703-17
pubmed: 18817471
Expert Opin Ther Targets. 2022 Jan;26(1):1-4
pubmed: 34936525
PLoS One. 2011 Jan 17;6(1):e14526
pubmed: 21264222
Biomaterials. 2013 Apr;34(13):3381-9
pubmed: 23391494
J Am Chem Soc. 2022 Jan 12;144(1):270-281
pubmed: 34968032
Cancer Lett. 2016 Oct 10;381(1):252-8
pubmed: 26742464
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):
pubmed: 29229669
Int J Nanomedicine. 2019 Sep 19;14:7643-7663
pubmed: 31571869
Front Bioeng Biotechnol. 2021 Jul 01;9:701504
pubmed: 34277592
J Immunol. 2002 Oct 15;169(8):4467-74
pubmed: 12370382
Int J Pharm. 2012 Feb 14;423(1):77-83
pubmed: 21575694
Adv Healthc Mater. 2018 Oct;7(19):e1800510
pubmed: 30101578
Zhonghua Yi Xue Za Zhi. 2009 May 12;89(18):1281-6
pubmed: 19595187